A Europe-based firm began as a support structure for an initial group of private investors interested in life sciences and grew into a platform that sources investment opportunities and represents several high net-worth individuals, as well as strategy partners. The firm’s network invests globally in biotherapeutic companies, primarily focusing on Seed to Series A stages, and expects to participate in a limited number of later stage investments, following the capital allocation desires of the private investor network. The firm’s investors typically invest as a group, with check sizes ranging from $1-3M USD with the intention to make up to 3 new investments per year.
The firm is focused on therapeutics but is modality and indication agnostic. This includes orphan diseases. Platform or multi-asset companies are often valued over single asset opportunities. Preferred stage of development varies based on the validation level of both the therapeutic target(s) and technology being applied. The more validated the targets and/or technology, the earlier the firm’s investor group is able to invest, including specific investment cases prior to pre-clinical animal efficacy.
The firm does not have specific management team requirements and has taken board seats in the past, however it is not a requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment